AIMIA TO REPORT FOURTH QUARTER AND FULL-YEAR 2024 RESULTS ON MARCH 28
Werte in diesem Artikel
TORONTO, March 11, 2025 /CNW/ - Aimia Inc. (TSX: AIM) will announce its fourth quarter and full-year financial results for the period ended December 31, 2024 on Friday, March 28, 2025.
Aimia's financial results are expected to be released at approximately 7:00 am ET followed by a live presentation by management via a webcast and teleconference call at 8:30 am ET the same day.
Aimia Q4 Earnings Conference Call/Webcast
- Time: 8:30m ET
- Date: March 28, 2025
- The presentation will be available in a listen-only mode via:
- Telephone at 1-888-699-1199 (North America) or 416-945-7677 (internationally)
- Webcast at https://app.webinar.net/MmPwKJ49k0R
- Presentation materials to be referenced during the call will be available from the Company's website at https://www.aimia.com/investor-relations/events-presentations/
- Listeners are encouraged to dial-in/log-in 15 minutes prior to start of the presentation to secure a line or test their connection.
An archive of the Aimia's Q4 earnings presentation will be available from the Company's website.
About Aimia
Aimia Inc. (TSX: AIM) is a diversified company focused on unlocking the growth potential of its two global businesses, Bozzetto, a sustainable specialty chemicals company, and Cortland International, a rope and netting solutions company. Headquartered in Toronto, Aimia's priorities include monetizing its non-core investments, returning capital to its shareholders, and efficiently utilizing its loss carry-forwards to create shareholder value.
For more information about Aimia, visit www.aimia.com.
SOURCE Aimia Inc.
Ausgewählte Hebelprodukte auf Hemispherx Biopharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hemispherx Biopharma
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Hemispherx Biopharma Inc Registered Shs
Analysen zu Hemispherx Biopharma Inc Registered Shs
Keine Analysen gefunden.